Dept of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden
Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Eur Respir J. 2022 Feb 17;59(2). doi: 10.1183/13993003.00142-2021. Print 2022 Feb.
Asthma phenotyping requires novel biomarker discovery.
To identify plasma biomarkers associated with asthma phenotypes by application of a new proteomic panel to samples from two well-characterised cohorts of severe (SA) and mild-to-moderate (MMA) asthmatics, COPD subjects and healthy controls (HCs).
An antibody-based array targeting 177 proteins predominantly involved in pathways relevant to inflammation, lipid metabolism, signal transduction and extracellular matrix was applied to plasma from 525 asthmatics and HCs in the U-BIOPRED cohort, and 142 subjects with asthma and COPD from the validation cohort BIOAIR. Effects of oral corticosteroids (OCS) were determined by a 2-week, placebo-controlled OCS trial in BIOAIR, and confirmed by relation to objective OCS measures in U-BIOPRED.
In U-BIOPRED, 110 proteins were significantly different, mostly elevated, in SA compared to MMA and HCs. 10 proteins were elevated in SA MMA in both U-BIOPRED and BIOAIR (alpha-1-antichymotrypsin, apolipoprotein-E, complement component 9, complement factor I, macrophage inflammatory protein-3, interleukin-6, sphingomyelin phosphodiesterase 3, TNF receptor superfamily member 11a, transforming growth factor-β and glutathione S-transferase). OCS treatment decreased most proteins, yet differences between SA and MMA remained following correction for OCS use. Consensus clustering of U-BIOPRED protein data yielded six clusters associated with asthma control, quality of life, blood neutrophils, high-sensitivity C-reactive protein and body mass index, but not Type-2 inflammatory biomarkers. The mast cell specific enzyme carboxypeptidase A3 was one major contributor to cluster differentiation.
The plasma proteomic panel revealed previously unexplored yet potentially useful Type-2-independent biomarkers and validated several proteins with established involvement in the pathophysiology of SA.
哮喘表型学需要新的生物标志物发现。
通过应用新的蛋白质组学面板,从两个特征明确的严重哮喘(SA)和轻度至中度哮喘(MMA)、COPD 患者和健康对照(HC)队列的样本中,鉴定与哮喘表型相关的血浆生物标志物。
针对主要参与炎症、脂质代谢、信号转导和细胞外基质相关途径的 177 种蛋白的抗体阵列,应用于 U-BIOPRED 队列的 525 名哮喘患者和 HCs 的血浆中,并应用于 BIOAIR 队列的 142 名哮喘和 COPD 患者。通过 BIOAIR 中的 2 周、安慰剂对照的 OCS 试验确定口服皮质类固醇(OCS)的效果,并通过与 U-BIOPRED 中的客观 OCS 测量结果的关系进行验证。
在 U-BIOPRED 中,与 MMA 和 HCs 相比,SA 中有 110 种蛋白明显不同,大多数升高。在 U-BIOPRED 和 BIOAIR 中,SA MMA 中均有 10 种蛋白升高(α-1-抗胰蛋白酶、载脂蛋白-E、补体成分 9、补体因子 I、巨噬细胞炎症蛋白-3、白细胞介素-6、鞘磷脂磷酸二酯酶 3、TNF 受体超家族成员 11a、转化生长因子-β和谷胱甘肽 S-转移酶)。OCS 治疗降低了大多数蛋白,但在纠正 OCS 使用后,SA 和 MMA 之间的差异仍然存在。U-BIOPRED 蛋白数据的共识聚类产生了六个与哮喘控制、生活质量、血液中性粒细胞、高敏 C 反应蛋白和体重指数相关的聚类,但与 2 型炎症生物标志物无关。肥大细胞特异性酶羧肽酶 A3 是聚类分化的主要贡献者之一。
血浆蛋白质组学面板揭示了以前未探索但具有潜在用途的 2 型非依赖性生物标志物,并验证了几个与 SA 病理生理学有既定关系的蛋白。